Saluda Medical Announces $125M Equity Financing Led By Redmile Group Llc And New Investors Fidelity Management & Research Company Llc And T. Rowe Price Associates, Inc.
Saluda Medical Announces $125M Equity Financing Led By Redmile Group Llc And New Investors Fidelity Management & Research Company Llc And T. Rowe Price Associates, Inc.
03/02/22, 9:00 AM
Money raised
$125 million
Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile Group LLC as well as new investors Fidelity Management & Research Company LLC, and funds and accounts advised by T. Rowe Price Associates, Inc.
Company Info
Additional Info
Saluda Medical is a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders. The Company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally, by instantaneously reading, recording, and responding to the nerves' response to stimulation to provide continually optimized therapy. Evoke is an investigational device in the United States and is limited by federal law to investigational use. It is not available for sale in the United States and will not be available for sale until it is approved by the FDA. SCS is designed to treat chronic pain by stimulating the spinal cord and altering the transmission of pain signals to the brain. To learn more, visit www.saludamedical.com.
SOURCE Saluda Medical